By Severence MacLaughlin / Guest Contributor
The U.S. healthcare system isn’t just expensive, it’s inefficient in ways that actively drive avoidable harm. Every year, billions of dollars are spent managing advanced disease states that did not appear overnight. They developed quietly, over years, often with detectable signals long before patients ever crossed into crisis. Yet clinicians are still asked to intervene late, with limited visibility into what came before. The result is a system that reacts to decline instead of preventing it, when outcomes are harder to change and costs are far more difficult to contain.
The scale of the problem is staggering. U.S. healthcare spending grew to about $4.9 trillion in 2023 and accounted for nearly 18% of the nation’s GDP, yet outcomes continue to lag. About 90% of that spending goes toward managing and treating chronic and mental health conditions, many of which could be mitigated with earlier intervention. Meanwhile, peer-reviewed research suggests that up to 25% of total healthcare costs, roughly $760 billion to $935 billion annually, are wasteful, driven by inefficiencies and late-stage care that adds cost without improving health.
This isn’t a failure of effort or expertise. It’s a failure of timing.
For decades, clinical care has relied on symptoms, episodic testing, and point-in-time assessments. That approach made sense when early risk was difficult to quantify and longitudinal insight was out of reach. But healthcare has changed. Data availability has exploded. Computational power has matured. Today, predictive artificial intelligence can model disease trajectories well before symptoms appear, offering clinicians a clearer view of where a patient is headed, not just where they are.
The central challenge facing healthcare now is not whether predictive insight is possible, but whether the system is willing to act on it.
Chronic conditions like cardiovascular disease, kidney disease, diabetes, COPD, and depression do not begin at diagnosis. They progress gradually, shaped by compounding risk factors over time. Yet care models continue to treat the first major clinical event as the starting line. By the time symptoms surface, patients have often crossed biological thresholds that are difficult, and sometimes impossible, to reverse. This gap between early risk and late intervention is where preventable complications take hold.
The financial impact of this delay is substantial. Heart failure alone can add tens of thousands of dollars per patient each year in cardiac-related claims, with advanced cases reaching into the hundreds of thousands over time. Similar patterns appear across other chronic conditions, where downstream costs are routinely accepted as inevitable. In reality, these figures reflect missed opportunities to intervene earlier, when care is more effective and far less expensive.
Predictive AI changes what clinicians can see and when they can act. By analyzing large patient populations over time, predictive models surface early risk signals that traditional screening often misses. These tools do not replace clinical judgment. They augment it, offering clinicians clearer insight into which patients are likely to deteriorate and where proactive care can make the greatest difference.
Health systems that have adopted clinically validated predictive models are already seeing measurable results. Earlier intervention reduces preventable hospitalizations, slows disease progression, and improves long-term patient stability. Importantly, financial savings follow improved care, not cost-cutting. When systems stay ahead of decline, both patients and providers benefit.
And yet, predictive prevention remains the exception rather than the standard.
Many reimbursement structures and clinical workflows still reward intervention after deterioration instead of action before it. Providers are compensated for treating advanced illness, not for preventing it. As a result, preventable disease progression continues to strain clinicians, patients, and payers alike. The barrier is no longer technological readiness, it’s structural adoption.
Skepticism around artificial intelligence in healthcare is understandable. Clinicians and policymakers are right to question transparency, bias, and the risk of overreliance on automated systems. Poorly designed tools can create noise instead of clarity, eroding trust and clinical confidence. Any technology that influences care decisions must be held to rigorous standards of validation and ethical deployment.
But rejecting predictive tools outright carries its own risk. Clinically validated, responsibly designed AI enhances human expertise rather than replacing it. The answer is not less insight, but better integration, ensuring predictive intelligence delivers clear, actionable signals that clinicians can trust and use effectively. Ignoring early risk does not preserve the status quo; it guarantees continued preventable harm.
If healthcare reform is serious about improving outcomes while controlling costs, predictive intervention must become foundational, not optional. Embedding predictive analytics into standards of care allows clinicians to act earlier, patients to stay healthier, and systems to reduce preventable complications by design.
The tools already exist. What’s required now is the commitment to use them, before the next crisis, not after.
Severence MacLaughlin is the founder and CEO of DeLorean AI, a South Florida–based healthtech company pioneering predictive artificial intelligence to improve clinical decision-making and patient outcomes. Raised on a farm in Rhode Island, he brings a data-driven approach to healthcare, developing technologies that help providers detect disease earlier, reduce costs, and ultimately extend lives.
Refresh Miami welcomes locally relevant guest posts. Send your idea for a post to Nancy Dahlberg at [email protected]
